buyNotable
Charles Failla bought $1.0M of ALTIX
President, CEO and Sec at Align Alternative Access Fund. 100,000 shares at an average of $10.00, traded Jun 2, 2025, filed Dec 11, 2025.
Conviction score
65Value
$1.0M
100,000 shares
Holdings after
110,000
+1000% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +25RoleCEO
- +25Trade size$1.0M at market
- +10Relative to holdingsHoldings up 1000%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001580642-25-007796, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 2, 2025 | POpen-market purchase Class I Shares | +50,000 | $10.00 | $500k | 60,000 | Dec 11, 2025 |
| Jun 2, 2025 | POpen-market purchase Class I Shares | +10,000 | $10.00 | $100k | 70,000 | Dec 11, 2025 |
| Jun 2, 2025 | POpen-market purchase Class I Sharesindirect: Spouse | +40,000 | $10.00 | $400k | 110,000 | Dec 11, 2025 |
Related signals
Other insiders at Align Alternative Access Fund and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 37Weak | ALTIXbuy Align Alternative Access Fund | Jeffrey Leinan director | $280k 27,703 shares | - | |
| 49Moderate | ALTIXbuy Align Alternative Access Fund | Jeffrey Leinan director | $700k 68,627 shares | - | |
| 43Moderate | ALTIXbuy Align Alternative Access Fund | Charles Failla President, CEO and Secretary | $100k 10,000 shares | - |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.